Literature DB >> 2983124

Human leukocytes kill varicella-zoster virus-infected fibroblasts in the presence of murine monoclonal antibodies to virus-specific glycoproteins.

M Ito, T Ihara, C Grose, S Starr.   

Abstract

Seven murine monoclonal antibodies reacting with major glycoproteins of varicella-zoster virus were tested for functional activity in assays for antibody-dependent cellular cytotoxicity (ADCC) and antibody-plus-complement-mediated lysis. Human peripheral blood mononuclear cells killed varicella-zoster virus-infected fibroblasts in the presence of three of four monoclonal antibodies directed against gp98/62 and a single monoclonal antibody directed against gp118. Neither of two monoclonal antibodies directed against gp66 was able to mediate ADCC. In 18-h assays, adherent effector cells were more active than nonadherent effector cells in mediating ADCC. Adherent cells treated with anti-Leu-11b and complement retained their cytotoxic activity, suggesting that monocytes are responsible for most of the adherent-cell-mediated cytotoxicity. Both immunoglobulin G1 and G2a murine monoclonal antibodies were able to participate in ADCC. Of the two immunoglobulin G2a monoclonal antibodies tested, both of which reacted with gp98/62, only one mediated lysis in the presence of complement. These results indicate that some murine monoclonal antibodies against major glycoproteins of varicella-zoster virus have functional activity in cytotoxicity assays.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2983124      PMCID: PMC254766     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  15 in total

1.  Herpes simplex virus glycoproteins: participation of individual herpes simplex virus type 1 glycoprotein antigens in immunocytolysis and their correlation with previously identified glycopolypeptides.

Authors:  B Norrild; S L Shore; A J Nahmias
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

2.  Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence.

Authors:  V Williams; A Gershon; P A Brunell
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

3.  Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2.

Authors:  N Balachandran; S Bacchetti; W E Rawls
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

4.  Pretreatment of plastic Petri dishes with fetal calf serum. A simple method for macrophage isolation.

Authors:  K Kumagai; K Itoh; S Hinuma; M Tada
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

5.  Varicella-zoster virus-specific gp140: a highly immunogenic and disulfide-linked structural glycoprotein.

Authors:  C Grose; D P Edwards; K A Weigle; W E Friedrichs; W L McGuire
Journal:  Virology       Date:  1984-01-15       Impact factor: 3.616

6.  Antibody-dependent cell-mediated cytotoxicity against varicella-zoster virus-infected targets.

Authors:  H Kamiya; S E Starr; A M Arbeter; S A Plotkin
Journal:  Infect Immun       Date:  1982-11       Impact factor: 3.441

7.  Use of monoclonal antibodies for analysis of antibody-dependent immunity to ocular herpes simplex virus type 1 infection.

Authors:  J T Rector; R N Lausch; J E Oakes
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

8.  Human monocyte-macrophage-mediated antibody-dependent cytotoxicity to herpes simplex virus-infected cells.

Authors:  S Kohl; S E Starr; J M oleske; S L Shore; R B Ashman; A J Nahmias
Journal:  J Immunol       Date:  1977-03       Impact factor: 5.422

9.  Inactivation of varicella zoster virus in vitro: effect of leukocytes and specific antibody.

Authors:  A A Gershon; S P Steinberg
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

10.  Antibody responses to varicella-zoster virus and the role of antibody in host defense.

Authors:  A A Gershon; S P Steinberg
Journal:  Am J Med Sci       Date:  1981 Jul-Aug       Impact factor: 2.378

View more
  9 in total

1.  Transcription mapping of the varicella-zoster virus genome.

Authors:  J M Ostrove; W Reinhold; C M Fan; S Zorn; J Hay; S E Straus
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103

Review 2.  Glycoprotein E of pseudorabies virus and homologous proteins in other alphaherpesvirinae.

Authors:  L Jacobs
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

3.  Assembly and processing of the disulfide-linked varicella-zoster virus glycoprotein gpII(140).

Authors:  E A Montalvo; C Grose
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

4.  New common nomenclature for glycoprotein genes of varicella-zoster virus and their glycosylated products.

Authors:  A J Davison; C M Edson; R W Ellis; B Forghani; D Gilden; C Grose; P M Keller; A Vafai; Z Wroblewska; K Yamanishi
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

5.  Varicella-zoster virus p32/p36 complex is present in both the viral capsid and the nuclear matrix of the infected cell.

Authors:  W E Friedrichs; C Grose
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

6.  Neutralizing antibodies induced by recombinant vaccinia virus expressing varicella-zoster virus gpIV.

Authors:  A Vafai; W N Yang
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

7.  Recognition of similar epitopes on varicella-zoster virus gpI and gpIV by monoclonal antibodies.

Authors:  A Vafai; Z Wroblewska; R Mahalingam; G Cabirac; M Wellish; M Cisco; D Gilden
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

8.  Safety and Varicella Outcomes in In Utero-Exposed Newborns and Preterm Infants Treated With Varicella Zoster Immune Globulin (VARIZIG): A Subgroup Analysis of an Expanded-Access Program.

Authors:  Jennifer M Duchon; Myron J Levin; Anne A Gershon
Journal:  J Pediatric Infect Dis Soc       Date:  2020-09-17       Impact factor: 3.164

9.  New variant of varicella-zoster virus.

Authors:  Graham A Tipples; Gwen M Stephens; Chris Sherlock; Margrit Bowler; Benny Hoy; Darrel Cook; Charles Grose
Journal:  Emerg Infect Dis       Date:  2002-12       Impact factor: 6.883

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.